Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Carcinoma, Transitional Cell
  • Taxoids
  • Urinary Bladder Neoplasms

abstract

  • Eli Lilly and Company.

authors

publication date

  • November 18, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(17)32365-6

PubMed ID

  • 28916371

Additional Document Info

start page

  • 2266

end page

  • 2277

volume

  • 390

number

  • 10109